NCT06751329View on ClinicalTrials.gov

A Study of DM002 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

October 8, 2027

Study Completion Date

April 18, 2028

Conditions
Ovarian NeoplasmsProstatic NeoplasmsEndometrial NeoplasmsColorectal NeoplasmsSolid Carcinoma
Interventions
DRUG

DM002

An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W

Trial Locations (2)

2500

RECRUITING

Cancer Care Wollongong, Wollongong

77030

RECRUITING

The University of Texas, MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

INDUSTRY